DE60124387D1 - Synergistische kombination zur behandlung von kolorektalkarzinom - Google Patents

Synergistische kombination zur behandlung von kolorektalkarzinom

Info

Publication number
DE60124387D1
DE60124387D1 DE60124387T DE60124387T DE60124387D1 DE 60124387 D1 DE60124387 D1 DE 60124387D1 DE 60124387 T DE60124387 T DE 60124387T DE 60124387 T DE60124387 T DE 60124387T DE 60124387 D1 DE60124387 D1 DE 60124387D1
Authority
DE
Germany
Prior art keywords
treatment
colorectal carcinoma
synergistic combination
derivative
camptothecin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60124387T
Other languages
English (en)
Other versions
DE60124387T2 (de
Inventor
Marie-Christine Bissery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Enterprises SARL
Original Assignee
Pfizer Enterprises SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Enterprises SARL filed Critical Pfizer Enterprises SARL
Application granted granted Critical
Publication of DE60124387D1 publication Critical patent/DE60124387D1/de
Publication of DE60124387T2 publication Critical patent/DE60124387T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
DE60124387T 2000-02-28 2001-02-26 Synergistische pharmazeutische Zusammensetzungen zur Behandlung von kolorektalem Krebs Expired - Fee Related DE60124387T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18537800P 2000-02-28 2000-02-28
US185378P 2000-02-28
US20893800P 2000-06-05 2000-06-05
US208938P 2000-06-05
PCT/EP2001/002723 WO2001062235A2 (en) 2000-02-28 2001-02-26 A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer

Publications (2)

Publication Number Publication Date
DE60124387D1 true DE60124387D1 (de) 2006-12-21
DE60124387T2 DE60124387T2 (de) 2007-10-11

Family

ID=26881090

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60124387T Expired - Fee Related DE60124387T2 (de) 2000-02-28 2001-02-26 Synergistische pharmazeutische Zusammensetzungen zur Behandlung von kolorektalem Krebs

Country Status (28)

Country Link
US (3) US6503889B2 (de)
EP (1) EP1278518B1 (de)
JP (1) JP2003523980A (de)
KR (1) KR100717916B1 (de)
CN (1) CN1424912A (de)
AT (1) ATE344670T1 (de)
AU (1) AU785467B2 (de)
BR (1) BR0108728A (de)
CA (1) CA2401191C (de)
CY (1) CY1105803T1 (de)
CZ (1) CZ298259B6 (de)
DE (1) DE60124387T2 (de)
DK (1) DK1278518T3 (de)
EA (1) EA005619B1 (de)
EE (1) EE200200471A (de)
ES (1) ES2273841T3 (de)
HR (1) HRP20020658A2 (de)
HU (1) HUP0300848A3 (de)
IL (1) IL150953A0 (de)
MX (1) MXPA02008355A (de)
NO (1) NO324772B1 (de)
NZ (1) NZ520593A (de)
PL (1) PL363110A1 (de)
PT (1) PT1278518E (de)
SK (1) SK12242002A3 (de)
TW (1) TWI239841B (de)
WO (1) WO2001062235A2 (de)
YU (1) YU64602A (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20030092608A1 (en) * 2001-08-21 2003-05-15 Takayuki Kawaguchi Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
US7026301B2 (en) * 2002-10-17 2006-04-11 New York University Method of orally treating inflammatory skin conditions with prodrugs of 5-fluorouracil
ITMI20030317A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale.
US20050153885A1 (en) * 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
RS50692B (sr) * 2003-11-13 2010-06-30 Pharma Mar S.A.U. Kombinacija et-743 sa prolekovima 5-fluorouracila za lečenje kancera
CA2563502A1 (en) 2004-04-09 2005-10-20 Chugai Seiyaku Kabushiki Kaisha Novel water-soluble prodrug
JP2008501007A (ja) * 2004-05-28 2008-01-17 ファイザー・プロダクツ・インク 異常な細胞増殖を治療するための方法
KR20070034536A (ko) * 2004-06-04 2007-03-28 스미스클라인 비이참 (코르크) 리미티드 암 치료 방법
WO2005117980A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
DE112006000873T5 (de) * 2005-04-12 2008-03-06 Elan Pharma International Ltd. Zusammensetzungen mit modifizierter Freisetzung, umfassend ein Fluorcytidin-Derivate zur Behandlung von Krebs
BRPI0613796A2 (pt) * 2005-06-07 2011-02-15 Univ Yale composicões farmacêuticas e seus usos, e métodos de tratamento de cáncer e outras condições ou estados patológicos, por meio do uso de clevudina (lfmau) e telbivudina (ldt)
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
WO2010129545A2 (en) 2009-05-04 2010-11-11 Psivida Us, Inc. Porous silicon drug-eluting particles
HUE027831T2 (en) * 2010-03-12 2016-11-28 Genzyme Corp Combination therapy for breast cancer
CN104622790A (zh) 2010-11-01 2015-05-20 普西维达公司 用于递送治疗剂的可生物侵蚀的硅基装置
WO2014151381A1 (en) 2013-03-15 2014-09-25 Psivida Us, Inc. Bioerodible silicon-based compositions for delivery of therapeutic agents

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57116015A (en) 1981-01-09 1982-07-19 Yakult Honsha Co Ltd Antitumor agent
US4399276A (en) 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
JPS57116074A (en) 1981-01-09 1982-07-19 Yakult Honsha Co Ltd Novel camptothecin derivative and its preparation
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS58154582A (ja) 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
JPS595188A (ja) 1982-06-30 1984-01-12 Yakult Honsha Co Ltd １０−ヒドロキシカンプトテシンの製造法
JPS5951289A (ja) 1982-09-17 1984-03-24 Yakult Honsha Co Ltd 新規な９−置換−カンプトテシン誘導体
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US4981968A (en) 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
CA1332413C (en) 1987-06-25 1994-10-11 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
JPH0615547B2 (ja) 1988-01-20 1994-03-02 株式会社ヤクルト本社 新規なカンプトテシン誘導体
JP2524804B2 (ja) 1988-03-29 1996-08-14 株式会社ヤクルト本社 新規なカンプトテシン誘導体及びその製造法
JP2524803B2 (ja) 1988-03-29 1996-08-14 株式会社ヤクルト本社 新規なカンプトテシン誘導体およびその製造法
US5552154A (en) * 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
DE69209969T2 (de) 1991-10-29 1996-09-12 Glaxo Wellcome Inc Wasserlösliche Camptothecinderivate
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
GB9510716D0 (en) 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
US5670500A (en) 1995-05-31 1997-09-23 Smithkline Beecham Corporation Water soluble camptothecin analogs
US5663177A (en) 1995-05-31 1997-09-02 Smithkline Beecham Corporation Water soluble camptothecin analogs
DK0835258T3 (da) 1995-06-21 2003-02-03 Sod Conseils Rech Applic Hidtil ukendte camptothecin-analoger, fremgangsmåder til fremstilling heraf, anvendelse heraf som lægemidler og farmaceutiske præparater indeholdende disse
IL143920A0 (en) * 1998-12-31 2002-04-21 Sugen Inc 3-heteroarylidenyl-2-indolinone derivatives and pharmaceutical compositions containing the same
US6191119B1 (en) 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds

Also Published As

Publication number Publication date
CZ298259B6 (cs) 2007-08-08
HUP0300848A3 (en) 2005-03-29
CY1105803T1 (el) 2011-02-02
PT1278518E (pt) 2007-01-31
US20020068743A1 (en) 2002-06-06
ATE344670T1 (de) 2006-11-15
HUP0300848A2 (hu) 2003-08-28
HRP20020658A2 (en) 2004-12-31
NZ520593A (en) 2004-10-29
CA2401191A1 (en) 2001-08-30
NO20024076D0 (no) 2002-08-27
NO20024076L (no) 2002-08-27
CZ20022892A3 (cs) 2002-11-13
US6503889B2 (en) 2003-01-07
NO324772B1 (no) 2007-12-10
KR20020082856A (ko) 2002-10-31
WO2001062235A2 (en) 2001-08-30
ES2273841T3 (es) 2007-05-16
DE60124387T2 (de) 2007-10-11
US20030096789A1 (en) 2003-05-22
AU6011101A (en) 2001-09-03
MXPA02008355A (es) 2002-12-13
IL150953A0 (en) 2003-02-12
US6664242B2 (en) 2003-12-16
EA005619B1 (ru) 2005-04-28
PL363110A1 (en) 2004-11-15
CA2401191C (en) 2006-05-02
SK12242002A3 (sk) 2003-02-04
EP1278518B1 (de) 2006-11-08
YU64602A (sh) 2005-06-10
BR0108728A (pt) 2003-12-30
EE200200471A (et) 2003-12-15
CN1424912A (zh) 2003-06-18
DK1278518T3 (da) 2007-01-15
US20020091132A1 (en) 2002-07-11
EP1278518A2 (de) 2003-01-29
AU785467B2 (en) 2007-07-26
EA200200922A1 (ru) 2003-04-24
KR100717916B1 (ko) 2007-05-11
JP2003523980A (ja) 2003-08-12
TWI239841B (en) 2005-09-21
WO2001062235A3 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
DE60124387D1 (de) Synergistische kombination zur behandlung von kolorektalkarzinom
ATE322265T1 (de) Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
DK1169059T3 (da) Docetaxel i kombination med rhuMAb HER2 til behandling af cancere
NO20024610L (no) Synergistiske metoder og blandinger for behandling av kreft
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
NO20054988D0 (no) Preparater og metoder for behandling av cancer
TR200101481T2 (tr) Doğal bitkisel zaruri yağlar kullanan kanser tedavi kompozisyonu ve yöntemi.
DE60222137D1 (de) Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen
ATE332136T1 (de) Mittel, wie nikotinamide oder cadpr zur behandlung von hautkrankheiten
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
DK1017675T3 (da) Stærkt lipofile camptothecinderivater
EP1503748A4 (de) Arzneimittel zur linderung durch taxan induzierte neurotoxizität
DK1383516T3 (da) Indgivelse af et polysaccharid samtidig med et kemoterapeutisk middel til behandling af cancer
HUP0203153A2 (hu) Kombinációs kemoterápia
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
HUP0302629A2 (hu) Camptotechin és sztilbénszármazékok kombinációját tartalmazó gyógyszerkészítmények rák kezelésére
NO20055888L (no) Kombinasjonsterapi
IL164356A (en) Use of alpha- bromo or alpha-chloro acryloyl distamycin derivatives in the preparation of medicaments for treating cancer
MXPA05002477A (es) Asialo-interferones y el tratamiento de cancer de higado.
PT1313500E (pt) Associacoes de dalfopristina/quinupristina com o cefpirome

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee